Evidence map›Paper›PMID 36093713›Full record

ReviewJournal of Alzheimer's disease : JAD2022

Cognitive Resilience in Brain Health and Dementia Research.

Mahesh S Joshi, James E Galvin

Abstract readReview
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Advancing brain health equity with Indigenous peoples: A critical imperative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  9. Article
  10. Sleep duration promotes resistance and resilience to tau in older women at risk for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. The role of bilingualism on functional decline and neurodegeneration in distinct ADRD clinical syndromes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. AI-enabled resilience modeling for brain health.Frontiers in molecular medicine · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. APOE ε4 carrier status moderates the effect of lifestyle factors on cognitive reserve.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mahesh S JoshiComprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA.
James E GalvinComprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA.

Funding

Multicultural Community Dementia ScreeningR01AG071514 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2021 to 2025
$13.8M
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural PopulationR01NS101483 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2019 to 2023
$8.0M
Deep Phenotypic Characterization of Prodromal Dementia with Lewy BodiesR56AG074889 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2022 to 2022
$3.2M
NIA NIH HHS R01 AG071514NIA NIH HHS R56 AG074889NINDS NIH HHS R01 NS101483
6 · The paper itself

Abstract

With the expected rise in Alzheimer's disease and related dementias (ADRD) in the coming decades due to the aging population and a lack of effective disease-modifying treatments, there is a need for preventive strategies that may tap into resilience parameters. A wide array of resilience strategies has been proposed including genetics, socioeconomic status, lifestyle modifications, behavioral changes, and management of comorbid disease. These different strategies can be broadly classified as distinguishing between modifiable and non-modifiable risk factors, some of which can be quantified so that their clinical intervention can be effectively accomplished. A clear shift in research focus from dementia risk to addressing disease resistance and resilience is emerging that has provided new potential therapeutic targets. Here we review and summarize the latest investigations of resilience mechanisms and methods of quantifying resilience for clinical research. These approaches include identifying genetic variants that may help identify novel pathways (e.g., lipid metabolism, cellular trafficking, synaptic function, inflammation) for therapeutic treatments and biomarkers for use in a precision medicine-like regimen. In addition, innovative structural and molecular neuroimaging analyses may assist in detecting and quantifying pathological changes well before the onset of clinical symptoms setting up the possibility of primary and secondary prevention trials. Lastly, we summarize recent studies demonstrating the study of resilience in caregivers of persons living with dementia may have direct and indirect impact on the quality of care and patient outcomes.

Indexed as

Alzheimer DiseaseAgedAgingBrainCognitionHumansLife StyleAlzheimer’s diseasebiomarkersbrain healthcognitioncognitive reservedementianeuroimagingresilience

Identifiers

PMID36093713
PMCPMC10515194

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.